20:
multidrug resistance (MDR) testing and hence may become a viable treatment for endocrine-related cancers. A cocktail of pendant drugs could be delivered by water-soluble polymer platforms. The physical and chemical properties of the polymers used in polymer-drug conjugates are specially synthesized to flow through the kidneys and liver without being filtered out, allowing the drugs to be used more effectively. Traditional polymers used in polymer-drug conjugates can be degraded through enzymatic activity and acidity. Polymers are now being synthesized to be sensitive to specific enzymes that are apparent in diseased tissue. The drugs remain attached to the polymer and are not activated until the enzymes associated with the diseased tissue are present. This process significantly minimizes damage to healthy tissue.
53:
synthesized to either have degradable or non-degradable chemical bonds with their associated drug. To obtain many of many of these bonds the use of peptides or amino acids. There is a strong desire to synthesize polymeric conjugates with bioactive components and other drugs. The tendency of polymer drug conjugate to react with the proper type cell(s) needs to still be worked on, despite many current advances.
73:
and platinates have been clinically tested in drug conjugates. Due to successful clinical proof-of-concept, second-generation conjugates are now being developed. Experimental chemotherapy and novel polymer-based combinations are currently under investigation. Instead of passive targeting developed so
52:
copolymers have been successful in medical research. Recently there has been a growing interest in polymer conjugation with biologically active components. Such conjugates usually accumulate in tumors and can reduce toxicity in the body. Depending on the desired location, polymer conjugates can be
19:
are nano-medicine products under development for cancer diagnosis and treatment. There are more than 10 anticancer conjugates in clinical development. Polymer-drug conjugates are drug molecules held in polymer molecules, which act as the delivery system for the drug. Polymer drugs have passed
28:
Most typical deliver of drugs is through the mouth, skin, transmucosal and inhalation. Drug polymer conjugate follow these to some degree, but they are usually administered via injection. Many enzymes in the body decompose the drug if the drug is taken by other means.
48:
Polymers are used for the delivery of drugs and proteins. Some types of polymers being tested now are poly(ethylene glycol) (PEG), N-(2-hydroxypropyl)methacrylamide (HPMA), and
45:
compared to current treatments. Doses up to 1680 mg/m2 observed no cardiotoxicity. Antitumor behavior was observed at 80–320 mg/m2 of doxorubicin.
77:
A natural polymer dextrin and pendant chain polyacetals, have shown ability of pH-dependent degradation after incorporation into cell compartments. Also
115:
38:
155:
Bertrand, Nicolas; Leroux, Jean-Christope (2012). "The
Journey of a Drug-carrier in the Body: An Anatomo-physiological Perspective".
213:
Duncan, R; Vincent, M J (2005). "Polymer-drug
Conjugates: Towards a Novel Approach for the Treatment of Endrocrine-related Cancer".
74:
far, new approaches will provide receptor-mediated delivery. This will enable selective delivery of anticancer conjugates.
336:
192:
Targeted drug delivery by novel polymer-drug conjugates containing linkers cleavable by disease-associated enzymes
215:
254:
Khandare, Jayant; Minko, Tamara (April 2006). "Polymer–drug conjugates: Progress in polymeric prodrugs".
78:
312:
236:
172:
137:
302:
294:
263:
228:
195:
164:
127:
119:
82:
81:
conjugates can undergo pH-dependent degradation. Polymer-Directed Enzyme
Prodrug Therapy (
307:
282:
267:
224:
132:
103:
330:
42:
70:
168:
62:
66:
316:
240:
176:
141:
298:
41:
copolymer-doxorubicin (PK1; FCE28068) shows up to a 5 times reduction in
232:
199:
123:
49:
283:"Polymer-drug conjugates as modulators of cellular apoptosis"
61:
By now only traditional chemotherapeutic agents like
104:"Anticancer nanoparticulate polymer-drug conjugate"
85:) is an example of two-step anticancer treatment.
8:
108:Bioengineering & Translational Medicine
306:
131:
39:N-(2-Hydroxypropyl) methacrylamide (HPMA)
116:American Institute of Chemical Engineers
94:
7:
157:Institute of Pharmaceutical Sciences
268:10.1016/j.progpolymsci.2005.09.004
14:
50:poly(lactide-co-glycolide) (PLGA)
57:Novel Polymer-Based Combinations
281:Vicent, Maria J. (June 2007).
1:
169:10.1016/j.jconrel.2011.09.098
256:Progress in Polymer Science
43:anthracycline type toxicity
353:
102:Feng, Q; Tong, R (2016).
79:diethylstilboestrol (DES)
216:Endocrine-Related Cancer
17:Polymer-drug conjugates
33:Currently Being Tested
337:Antineoplastic drugs
299:10.1208/aapsj0902022
233:10.1677/erc.1.01045
190:Chau, Ying (2005).
124:10.1002/btm2.10033
24:Method of delivery
37:The polymer-drug
344:
321:
320:
310:
293:(2): E200–E207.
287:The AAPS Journal
278:
272:
271:
251:
245:
244:
210:
204:
203:
187:
181:
180:
152:
146:
145:
135:
99:
352:
351:
347:
346:
345:
343:
342:
341:
327:
326:
325:
324:
280:
279:
275:
253:
252:
248:
212:
211:
207:
189:
188:
184:
154:
153:
149:
101:
100:
96:
91:
59:
35:
26:
12:
11:
5:
350:
348:
340:
339:
329:
328:
323:
322:
273:
262:(4): 359–397.
246:
225:Bioscientifica
205:
182:
147:
93:
92:
90:
87:
58:
55:
34:
31:
25:
22:
13:
10:
9:
6:
4:
3:
2:
349:
338:
335:
334:
332:
318:
314:
309:
304:
300:
296:
292:
288:
284:
277:
274:
269:
265:
261:
257:
250:
247:
242:
238:
234:
230:
226:
222:
218:
217:
209:
206:
201:
197:
193:
186:
183:
178:
174:
170:
166:
163:(2): 152–63.
162:
158:
151:
148:
143:
139:
134:
129:
125:
121:
117:
113:
109:
105:
98:
95:
88:
86:
84:
80:
75:
72:
71:camptothecins
68:
64:
56:
54:
51:
46:
44:
40:
32:
30:
23:
21:
18:
290:
286:
276:
259:
255:
249:
220:
214:
208:
200:1721.1/32332
191:
185:
160:
156:
150:
111:
107:
97:
76:
60:
47:
36:
27:
16:
15:
227:: 189–199.
118:: 277–296.
63:doxorubicin
194:(Thesis).
89:References
67:paclitaxel
331:Category
317:17907762
241:16113096
177:22001607
142:29313017
308:2751409
133:5689533
315:
305:
239:
175:
140:
130:
114:(3).
83:PDEPT
313:PMID
237:PMID
173:PMID
138:PMID
303:PMC
295:doi
264:doi
229:doi
196:hdl
165:doi
161:161
128:PMC
120:doi
333::
311:.
301:.
289:.
285:.
260:31
258:.
235:.
223:.
221:12
219:.
171:.
159:.
136:.
126:.
110:.
106:.
69:,
65:,
319:.
297::
291:9
270:.
266::
243:.
231::
202:.
198::
179:.
167::
144:.
122::
112:1
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.